Integrating the Latest Evidence in Melanoma Care to Address Health Equity
June 30, 2023
June 30, 2024
This activity is provided by Talem Health and RME Collaborative.
This online program is recorded content from the live session at Oncology Congress and is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Eisai, Inc.; GlaxoSmithKline; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; and Seagen. This activity is supported by independent medical education grants from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. and Regeneron Pharmaceuticals, Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours (1.0 contact hour of pharmacotherapy credit)
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Early and correct identification of melanoma is key for ensuring patients have the best possible prognosis. However, rural and underserved areas face numerous challenges when accessing cancer care including workforce shortages, transportation barriers, and racial and ethnic disparities, leading to diagnostic delays and increased mortality compared with urban areas. Additionally, oncologists in these settings often find it challenging to stay abreast of the latest clinical advances, recommendations, and data. In this activity, expert faculty will review current and emerging treatment options for advanced and metastatic melanoma and evidence-based guidance for initial selection and sequencing of therapy. Strategies to improve management of adverse events and address health disparities in rural and underserved populations will also be discussed.
This enduring activity is a recorded session from Oncology Congress that took place on April 1, 2023.
Upon completion of this activity, participants should be better able to:
- Implement strategies to reduce melanoma health disparities in rural and underserved populations
- Apply clinical evidence and recommendations for initial treatment selection and sequencing of therapy for patients with metastatic melanoma
- Develop a plan for preventing, monitoring, and mitigating adverse events associated with treatments for advanced and metastatic melanoma
Michael A. Davies, MD, PhD
Professor and Chair
Department of Melanoma Medical Oncology
University of Texas MD Anderson Cancer Center
Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Joint Accreditation Statement
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 1.0 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Michael A. Davies, MD, PhD, has disclosed the following relevant financial relationships: consultant/advisory board member for ABM Therapeutics, Bristol Myers Squibb, Eisai, Inc., Genentech, Inc., Iovance, and Novartis Pharmaceuticals Corporation; grant/research support from ABM Therapeutics, Lead Pharma, and Pfizer, Inc.
Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
Instructions for Participation and Credit
This activity is offered at no cost to participants. To receive CME credit, participants must:
- Read the CME/CE information, including learning objectives and disclosure statements.
- Complete the pre-test.
- View the online activity.
- Complete the post-test and evaluation form.
A post-test score of 75% or higher is required to obtain credit. Your certificate will be made available for immediate download.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.
There is no fee for this educational activity.
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or [email protected].